Lenvatinib With Immunotherapy: — The Combination Explained

The tablet — lenvatinib — and the infusion — pembrolizumab — work by completely different mechanisms, and the evidence shows that using both at once is more effective for certain cancers than using either alone. Lenvatinib changes the tumour's blood supply and surrounding environment in a way that appears to help the immune cells activated by pembrolizumab reach the cancer more easily. Taking both together is the intended regimen, not an overlap.

Lenvatinib and pembrolizumab are used together for certain types of endometrial cancer and kidney cancer, and are being studied in other solid tumours. Whether this combination applies to your diagnosis depends on your cancer type, stage, and test results — your oncologist will explain the specific indication. Both NCCN and ESMO include this regimen in their guidance for cancers where the evidence supports it.

The evidence suggests the opposite. Lenvatinib appears to make the tumour environment more accessible to immune cells, which supports pembrolizumab's effect rather than blocking it. This is the biological rationale for combining them. The regimen was tested in clinical trials before being adopted into NCCN and ESMO guidance — your oncologist would not prescribe drugs likely to counteract each other.

The most common effects of lenvatinib include high blood pressure, fatigue, reduced appetite, and soreness on the palms and soles of the feet. Pembrolizumab can cause immune-related reactions affecting the gut, liver, lungs, skin, or thyroid. On both drugs together, you may experience effects from either or both. Tell your team promptly about any new symptom — particularly diarrhoea, shortness of breath, skin rash, or joint pain — because immune reactions need to be identified early.

Yes. Pembrolizumab is administered as day care at CION centres, so you do not need to stay overnight for the infusion. Lenvatinib is a tablet managed at home with monitoring support from your clinical team. Response-assessment scans such as PET-CT are coordinated with partner imaging centres. Your care team at your nearest CION centre can walk you through your specific schedule and what to expect at each visit.

Tell your oncologist about all medicines you currently take — including supplements, herbal preparations, and anything bought without a prescription. Lenvatinib in particular interacts with a number of substances. Also mention any history of high blood pressure, heart conditions, liver disease, or autoimmune conditions, as these affect how your team monitors you. If you are taking any traditional or herbal remedies, tell your team rather than stopping them on your own — the conversation matters more than stopping.